Salvage Magnetic Resonance Imaging–guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer
2024

MRI-guided Ultrasound Treatment for Prostate Cancer

Sample size: 39 publication Evidence: moderate

Author Information

Author(s): Anttinen Mikael, Mäkelä Pietari, Nurminen Pertti, Pärssinen Heikki, Malaspina Simona, Sainio Teija, Högerman Mikael, Taimen Pekka, Blanco Sequeiros Roberto, Boström Peter J.

Primary Institution: University of Turku and Turku University Hospital, Turku, Finland

Hypothesis

Salvage magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (sTULSA) is effective for localized radiorecurrent prostate cancer.

Conclusion

sTULSA is effective for radiorecurrent prostate cancer, but significant genitourinary toxicity is a concern.

Supporting Evidence

  • 89% of patients showed no cancer in the targeted area at 12 months.
  • Median PSA reduction was 95% at 12 months.
  • 56% of patients experienced adverse events, with severe genitourinary toxicity in 28%.

Takeaway

This study looked at a new treatment for prostate cancer that came back after radiation. It worked well for most patients, but some had serious side effects.

Methodology

This phase 2 study involved men with biochemically relapsed prostate cancer who underwent MRI-guided transurethral ultrasound ablation, with follow-up assessments at 12 months.

Potential Biases

Potential bias due to the single-center study design.

Limitations

Single-arm design and moderate sample size.

Participant Demographics

Median age of participants was 73 years, with 41% receiving hormonal therapy.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% (0.93–1.00)

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1016/j.euros.2024.11.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication